Who are Baseline ART's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TAF with a boosted protease inhibitor, ZDV+3TC+LPV/r, Multiple Product PrEP Program, Telbivudine (Standard of Care), NAs+IFN-α, Tenofovir alafenamide(TAF).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/baseline-art.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Baseline ART — Competitive Intelligence Brief

Baseline ART (Baseline ART) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitors (NRTIs). Area: Infectious Diseases.

phase 2 Nucleoside reverse transcriptase inhibitors (NRTIs) Reverse transcriptase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Baseline ART (Baseline ART) — Frontier Biotechnologies Inc.. Baseline ART works by suppressing the replication of the human immunodeficiency virus (HIV) through the inhibition of reverse transcriptase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Baseline ART TARGET	Baseline ART	Frontier Biotechnologies Inc.	phase 2	Nucleoside reverse transcriptase inhibitors (NRTIs)	Reverse transcriptase
TAF with a boosted protease inhibitor	TAF with a boosted protease inhibitor	University of Colorado, Denver	marketed	Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor)	HIV reverse transcriptase and HIV protease
ZDV+3TC+LPV/r	ZDV+3TC+LPV/r	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
Telbivudine (Standard of Care)	Telbivudine (Standard of Care)	Nanfang Hospital, Southern Medical University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
NAs+IFN-α	NAs+IFN-α	Beijing 302 Hospital	marketed	Antiviral combination therapy	Hepatitis B virus reverse transcriptase; interferon-alpha receptor signaling
Tenofovir alafenamide(TAF)	Tenofovir alafenamide(TAF)	Humanity and Health Research Centre	marketed	Nucleotide reverse transcriptase inhibitor (NtRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitors (NRTIs) class)

Frontier Biotechnologies Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baseline ART — Competitive Intelligence Brief. https://druglandscape.com/ci/baseline-art. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab